# Targeting cancer-stroma interactions in breast cancer metastasis using organotypic modeling

> **NIH NIH F31** · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $34,127

## Abstract

Project Summary / Abstract
Metastatic breast cancer remains challenging to treat and the 5-year survival rate for patients diagnosed with
distant metastasis is below 30%. Targeting later stages of breast cancer (BC) metastasis present important
opportunities for therapeutic interventions that has the potential to improve patient-outcomes. However, the
molecular mechanisms by which tumor cells extravasate out of endothelial vessels and interact with surrounding
tissue of the secondary metastatic site are still unclear. Furthermore, how interactions between tumor and
stromal cells in the metastatic microenvironment contribute to differential therapeutic response remain
unestablished. Current in vivo approaches from studying BC metastasis are costly, has lengthy read-out time to
affect clinical decisions, and is inherently low-throughput. Moreover, the lack of availability of in vitro models that
effectively characterize the host-specific multi-cellular interactions and signaling events observed in vivo makes
this technically challenging to investigate. Thus, there is a critical need for improved modeling approaches that
recapitulates the microenvironmental complexities of normal and diseased tissue and that can accurately predict
response to novel treatment options. The project goal is to develop innovative organotypic modelling
technologies to identify key tumor-stroma targets influencing BC cell extravasation and growth in the lung. The
proposed work will test the hypothesis that tumor-stroma interactions can be targeted to inhibit BC cell
extravasation and growth and that by means of organotypic modeling approaches unique sets of interactions
can be identified and targeted using a novel combination of therapeutic drugs. The study will explore the following
two aims. Aim1 Identify cancer-induced response of the lung microenvironment influencing cancer extravasation
and growth behavior. Interactions between BC cells and multiple components of the lung stroma including
macrophages, fibroblasts, epithelial cells and relevant extracellular matrices will be investigated. Cell responses
including BC extravasation rates, vascular permeability, protein and mRNA expression, cellular metabolism and
cytokine secretion will be evaluated. Aim2 Measure cancer and stromal cell response to novel drug combinations
targeting multiple interactions within the lung microenvironment to inhibit extravasation and growth of tumor cells.
Changes in cellular metabolism will be measured to quantify temporal dynamics of drug response and guide
downstream collection of biological responses defined in Aim1. The proposed work will help lay the foundation
for future clinical studies using patient-specific models to develop personalized therapy and assess their
predictive capability. The overall goal of this proposal is in alignment with the mission of NIH to develop new
enabling technologies to characterize pathogenesis of diseases and test new therapies. Training and research
g...

## Key facts

- **NIH application ID:** 10054096
- **Project number:** 5F31CA247248-02
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** Mouhita Humayun
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $34,127
- **Award type:** 5
- **Project period:** 2019-12-01 → 2021-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10054096

## Citation

> US National Institutes of Health, RePORTER application 10054096, Targeting cancer-stroma interactions in breast cancer metastasis using organotypic modeling (5F31CA247248-02). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10054096. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
